Immunohistochemical study of vasoactive intestinal peptide (VIP) enteric neurons in diabetic rats supplemented with L-glutamine.
The purpose of this work was to study the area of the varicosities of nerve fibers of myenteric neurons immunoreactive to vasoactive intestinal peptide (VIP-IR) and of the cell bodies of VIP-IR submucosal neurons of the jejunum of diabetic rats supplemented with 2% L-glutamine. Twenty male rats were divided into the following groups: normoglycemic (N), normoglycemic supplemented with L-glutamine (NG), diabetic (D) and diabetic supplemented with L-glutamine (DG). Whole-mounts of the muscle tunica and the submucosal layer were subjected to the immunohistochemical technique for neurotransmitter VIP identification. Morphometric analyses were carried out in 500 VIP-IR cell bodies of submucosal neurons and 2000 VIP-IR varicosities from each group. L-Glutamine supplementation to the normoglycemic animals caused an increase in the areas of the cell bodies (8.49%) and varicosities (21.3%) relative to the controls (P < 0.05). On the other hand, there was a decrease in the areas of the cell bodies (4.55%) and varicosities (28.9%) of group DG compared to those of group D (P < 0.05). It is concluded that L-glutamine supplementation was positive both to normoglycemic and diabetic animals.
Alves
Eder Paulo Belato
EP
Department of Morphophysiological Sciences, Laboratory of Enteric Neurons, State University of Maringa, Avenida Colombo, 5790 Bloco H-79, CEP 87020-900 Maringá, PR, Brazil. ederpaulo.uem@gmail.com
Alves
Angela Maria Pereira
AM
Pereira
Renata Virginia Fernandes
RV
de Miranda Neto
Marcílio Hubner
MH
Zanoni
Jacqueline Nelisis
JN
D000601:Amino Acids, Essential / Q000008:administration & dosage; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage; D001835:Body Weight; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D004032:Diet; D019587:Dietary Supplements; D017615:Enteric Nervous System / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D019084:Fluorescent Antibody Technique, Indirect; D005973:Glutamine / Q000008:administration & dosage*; D006442:Glycated Hemoglobin; D007583:Jejunum / Q000294:innervation* / Q000378:metabolism / Q000473:pathology; D008297:Male; D009197:Myenteric Plexus / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D009474:Neurons / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D020011:Protective Agents / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar; D013368:Submucous Plexus / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism*
D000601:Amino Acids, Essential; D000975:Antioxidants; D005973:Glutamine; D006442:Glycated Hemoglobin; D020011:Protective Agents; D014660:Vasoactive Intestinal Peptide